论文部分内容阅读
目的 :对中国非瓣膜性房颤患者使用吲哚布芬抗凝治疗进行药物经济学评价,为中国房颤患者抗凝治疗药物的合理选用提供依据。方法 :采用基于马尔可夫模型的成本效用分析,评价吲哚布芬与华法林在非瓣膜房颤患者抗凝治疗中考虑因避免出血事件带来死亡率、疾病经济负担的减少以及生命效用值的增加情况下的经济性。结果 :在均值估计的基础上,其效用值无论是否考虑年龄调整,200mg吲哚布芬相比于5mg华法林其期望成本更低的同时期望收益更高,具有绝对经济性。结论:目前在我国,与华法林相比,在非瓣膜性房颤患者使用吲哚布芬进行抗凝治疗时可以显现出经济性。
OBJECTIVE: To evaluate the pharmacokinetics of indobufen anticoagulant therapy in patients with non-valvular atrial fibrillation in China and provide evidence for the rational selection of anticoagulant drugs in patients with atrial fibrillation in China. METHODS: Cost-effectiveness analysis based on Markov models was used to evaluate the effects of indobufen and warfarin on anticoagulation in patients with non-valvular atrial fibrillation due to avoidance of mortality due to avoidance of bleeding, reduction in economic burden of illness, and life utility The economy of value increases. Results: Based on the mean estimate, the utility value indobufen is expected to have higher expected profit and lower absolute cost compared to 5 mg of warfarin, regardless of whether the age adjustment is taken into account or not, with absolute economy. Conclusions: At present, in China, compared with warfarin, the economy can be shown when using indobufen for anticoagulation in patients with non-valvular atrial fibrillation.